Health-care costs of losartan and candesartan in the primary treatment of hypertension

A recent study of two widely used angiotensin receptor blockers reported a reduced risk of cardiovascular events (−14.4%) when using candesartan compared with losartan in the primary treatment of hypertension. In addition to clinical benefits, costs associated with treatment strategies must be consi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Henriksson, M, Russell, D, Bodegard, J, Kjeldsen, S, Hasvold, P, Stålhammar, J, Levin, L-Å
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2011
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3023072/
https://ncbi.nlm.nih.gov/pubmed/20376078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jhh.2010.36
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki